Moderna, Inc. (NASDAQ:MRNA) Stake Lessened by Private Advisor Group LLC

Private Advisor Group LLC trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 20.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,454 shares of the company’s stock after selling 6,279 shares during the period. Private Advisor Group LLC’s holdings in Moderna were worth $1,634,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 15.1% during the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares in the last quarter. Capital World Investors raised its holdings in shares of Moderna by 0.5% during the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Mawer Investment Management Ltd. raised its holdings in shares of Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after acquiring an additional 120,621 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after acquiring an additional 463,960 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Moderna by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock worth $169,542,000 after acquiring an additional 29,566 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock worth $238,531 over the last quarter. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 0.9 %

Shares of MRNA opened at $54.72 on Thursday. The stock has a market cap of $20.97 billion, a price-to-earnings ratio of -3.52 and a beta of 1.66. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12 month low of $52.26 and a 12 month high of $170.47. The company has a 50-day moving average price of $66.34 and a two-hundred day moving average price of $102.02.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter last year, the company earned ($3.62) earnings per share. Equities analysts predict that Moderna, Inc. will post -9.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MRNA. Sanford C. Bernstein initiated coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Piper Sandler lowered their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a research report on Wednesday, August 28th. Finally, Barclays lowered their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $94.65.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.